

## Research Activities Newsletter

---

September 2023

### In the News: Congratulations to the following awardees!!



**Sarah Heavey**, Clinical Assistant Professor of Community Health and Health Behavior, received an extension of her Intergovernmental Personnel Act (IPA) agreement from VA WNY Healthcare System for the project entitled, *Exploring Connections between Chronic Pain, Opioid Use, and Medications for Opioid Use Disorder*. The project designs retrospective and mixed/methods studies and performs evaluations of services related to substance use disorders, chronic pain, and related concerns among Veterans.



**David Hostler**, Professor and Chair of Exercise and Nutrition Sciences, is PI on a new award from the U.S. Navy Office of Naval Research for the research project entitled, *Physiological Determinants of Performance During Simulated Shipboard Firefighting Activities*. During this study, the physiological responses to simulated shipboard firefighting tasks will be documented and the predictors of performance in a cohort of male and female subjects will be examined.



**Michael LaMonte**, Research Professor of Epidemiology and Environmental Health, is MPI on a continuation award from University of California at San Diego/NIH for the research project entitled, *Objective Physical Activity and Cardiovascular Health in Older Women: OPACH2*. The study will continue to build on the success of OPACH1 and further characterize the type, amount, and intensity of physical activity (PA) needed to maintain cardiovascular health in older adults. The findings could lead to transformed and refined guidelines by conveying accurate and realistic PA goals for older Americans.



**Lucia Leone**, Associate Professor of Community Health and Health Behavior, has received two awards. She is PI on a new award from the Nutrition & Obesity Policy Research and Evaluation Network (NOPREN) for the research project entitled, *Identifying Determinants of Food Prescription Program Implementation and Usage*. The research focuses on understanding determinants of food prescription program implementation and participation.

Dr. Leone also received a continuation of the diversity supplement to her current award from the National Cancer Institute/NIH for the research project entitled, *Effectiveness and Implementation of a Research Tested Mobile Produce Market Designed to Improve Diet in Underserved Communities*. This study will continue to implement a mobile produce market program with eight organizations nationwide to determine if the effect can be replicated. It also includes development of a best-practices toolkit to help others sustainably implement the program.




**Jeffrey Miecznikowski**, Associate Professor and Interim Chair of Biostatistics, is Co-Investigator on a new award from the National Cancer Institute/NIH (PI: Remi Adelaiye-Ogala, Medicine) for the research project entitled, *Therapeutic Targeting of Master Regulators in Non-Canonical AR Driven Advanced Lethal Prostate Cancers*. The immediate goal is to leverage information from molecular studies to recognize the subset of patients where resistance is driven by non-canonical AR activity using multi-omic-based markers. The long-term goal is to translate preclinical findings into the clinic in the setting of phase I & II clinical trials.

**Tammy Milillo**, Research Assistant Professor of Epidemiology and Environmental Health, is PI on a new project under the parent award entitled, *UB Soil Sample Study: Determining the Environmental Impact of Coke Oven Emissions Originating from Tonawanda Coke Corp. on*

*Surrounding Residential Community* (PI: Joseph Gardella, Chemistry) from the US District Court for the Western District of New York. This study will continue to investigate how pollution from the Tonawanda Coke Corp. plant impacted soil in surrounding communities. Findings from the research will benefit residents in Grand Island, the City of Tonawanda, the Town of Tonawanda and North Buffalo by providing them with information about what chemicals are in their soil, how widespread any pollution may be, and whether these pollutants may have originated at the Tonawanda Coke plant.



**Danelly Rodriguez**, predoctoral student in Epidemiology and Environmental Health, received a new fellowship award from the National Institute of Environmental Health Sciences/NIH for the research project entitled, *Executive Functions in Urban Hispanic/Latino Youth: Exposure to Mixture of Arsenic and Pesticides During Childhood*. **Katarzyna Kordas**, Associate Professor of EEH, serves as faculty sponsor.



**Jean Wactawski-Wende**, SUNY Distinguished Professor of Epidemiology and Environmental Health and Dean of SPHHP and Hailey Banack, Research Assistant Professor of Epidemiology and Environmental Health are MPIs on a new award from the National Institute on Aging/NIH for the research project entitled, *MASS: Muscle and Disease in Postmenopausal Women*. This study will address a key knowledge gap in the extent to which insulin-glucose homeostasis is associated with loss of muscle mass over time in aging women and whether this varies by race/ethnicity. The feedback loop between impaired insulin-glucose homeostasis and loss of skeletal muscle mass will also be examined.



Dr. Wactawski-Wende also is Co-Investigator on a continuation award from the National Institute of Dental & Craniofacial Research/NIH (PI: Keith Kirkwood, Periodontics and Endodontics) for the project entitled, *Immunometabolic Regulation of MDSCs in Periodontitis*. The study continues to work toward understanding the mechanisms that underpin the links between degree of obesity and periodontal disease incidence.

***In This Issue***

**In the News: Congratulations to the Following Awardees ..... 1**

**Grant Clinic ..... 3**

**NIH Funding Opportunities**

**Request for Applications (RFA) ..... 6**

**Program Announcements Reviews in an Institute (PAR).....10**

**Program Announcements.....14**

**Words to Live By ..... 15**

## Grant Clinic

### **NIH LOAN REPAYMENT PROGRAMS (LRP) APPLICATION CYCLE OPENED ON SEPTEMBER 1, 2023 and CLOSES ON NOVEMBER 16, 2023.**

Awardees can receive up to **\$100,000** of qualified educational debt repayment with a two-year contract. The NIH LRPs are unique programs, with tremendous benefit to early-stage researchers, so we strongly encourage those that were not successful in getting their applications funded to apply again.

Be sure to visit the LRP website [Home Page | National Institutes of Health | Division of Loan Repayment \(nih.gov\)](#) to learn more about eligibility requirements, application dates, and benefits of receiving an NIH LRP award!

[NOT-OD-23-142](#) – Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

[NOT-OD-23-144](#) – Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)

[NOT-OD-23-145](#) – Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH)

[NOT-OD-23-146](#) – Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to \$50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career. Extramural LRP applications will be accepted from September 1 until November 16, 2023.

## GENERAL NOTICE

[NOT-CA-23-091](#)

**Notice of Pre-Application Webinar for PAR-23-244: Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)**

The National Cancer Institute's Division of Cancer Control and Population Sciences (DCCPS) will hold a pre-application webinar for [PAR-23-244](#), "Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)." The pre-application webinar, to be held on **Thursday, October 19, 2023, from 2:00 pm - 3:00 pm ET**, will include an overview of the notice of funding opportunity (NOFO) as well as specific requirements for applications submitted in response to the NOFO.

[NOT-OH-23-002](#)

**Update for PAR-20-280 "Cooperative Research Agreements Related to the World Trade Center Health Program (U01)"**

The updated requirements, guidance, instructions, and other information for [PAR-20-280](#) are effective with the publication date of this notice.

[NOT-OH-23-003](#)

**Update for RFA-OH-22-004 "World Trade Center Health Research related to WTC Survivors (U01-No Applications with Responders Accepted)**

The Notice of Funding Opportunity (NOFO), [RFA-OH-22-004](#), is now closed, effective with the publication date of this notice. No more applications will be accepted for FY2024 and beyond. It is being reissued as [RFA-OH-24-003](#) "Exploratory/Developmental Grants Related to the World Trade Center Survivors (R21-No Applications with Responders Accepted)", which accepts new and resubmission applications with due date of December 5, 2023. Visit the [full NOFO](#) for information (also on [grants.gov](#) with FORMS-H application package preview).

## NOTICE OF INTENT TO PUBLISH

### [NOT-OD-23-174](#)

#### **Notice of Intent to Publish a funding Opportunity Announcement for Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)**

This NOFO is appropriate for ESIs who wish to initiate a research project in an area different from their previous research focus and/or training experience, and therefore have not produced preliminary data. Applications must include a separate attachment describing the change in research direction. PD/PI's who wish to proposed research projects consistent with their past work or training and/or supported by preliminary data, should apply to other NOFOs allowing for preliminary data. The NOFO is expected to be published in November 2023, with an expected first application due date in January 2024.

### [NOT-OD-23-175](#)

#### **Notice of Intent to Publish a Funding Opportunity Announcement for Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required)**

This announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” This research project supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this NOFO must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. The NOFO is expected to be published in November 2023, with an expected first application due date in January 2024.

### [NOT-CA-23-084](#)

#### **Notice of Intent to Publish a Funding Opportunity Announcement for Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SM) Populations**

The National Cancer Institute (NCI) intends to publish a NOFO that will support the rigorous assessment of the barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The NCI intends to solicit proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings. The NOFO is expected to be published in October 2023, with an expected first application due date in February 2024. Details of a planned pre-application webinar will be announced after the publication of the NOFO.

## NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

### [NOT-OD-23-170](#) – **Research Supplements to Promote Re-Entry, re-integration into, and Re-training in Health-Related Research Careers**

This NOSI is to provide information to the extramural community regarding an administrative supplement to provide full or part-time mentored research training experiences for individuals with high potential to re-enter, re-integrate into, or re-train in an active research career after an interruption for family responsibilities or other qualifying circumstances. The supplement grants are intended to provide these scientists with an opportunity to update or extend their research skills and knowledge and prepare them to re-establish or revitalize their careers in basic biomedical, behavioral, clinical, translational, or social science research. It is anticipated that by the completion of the supplement support period, the awardee will be prepared to apply for a fellowship (F), career development (K) award, a research award (R), SBIR/STTR, or other types of independent research support. This notice applies to due dates on or after **October 9, 2023**, and subsequent receipt dates through **October 9, 2026**.

### [NOT-CA-23-089](#) – **Mechanisms Driving Obesity and Prostate Cancer**

The purpose of this NOSI is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer (PCa) risk. About 80% of overall PCa is non-aggressive. The biologic mechanisms driving

both overall and aggressive PCa are uncertain. The identification of differences in the mechanisms driving aggressive vs. overall (mostly non-aggressive) disease are critical to optimizing clinical care among men who develop the disease. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 8, 2024**.

#### [NOT-DA-24-012](#) – **Xylazine: Understanding Its Use and the Consequences**

The purpose NOSI is to encourage research on the prevalence and consequences of xylazine co-use with opioids or opioid/stimulant combinations. This NOSI also encourages research into how xylazine impacts treatment of opioid use disorders and overdose. This notice applies to due dates on or after **October 16, 2023**, and subsequent receipt dates through **January 8, 2025**.

#### [NOT-OD-23-166](#) – **Research on Family Support and Rejection in the Health and Well-Being of SGM Populations**

The goal of this NOSI is to boost research on the impact and consequences of family rejection and family support on the health and well-being of SGM persons across the life course. Research proposed under this NOSI may include behavioral, social, clinical, implementation, basic, complementary, integrative, and any other relevant research approaches that probe the influences of family rejection, acceptance, affirmation, support, and belonging on the immediate and long-term health and health outcomes of SGM individuals at any life stage. This notice applies to due dates on or after **September 25, 2023**, and subsequent receipt dates through **May 8, 2026**.

#### [NOT-AA-23-018](#) – **Epidemiology and Prevention in Alcohol Research**

The purpose of this Notice is to solicit applications to advance basic, applied, translational, and methodological research on the epidemiology and prevention of hazardous alcohol consumption and related behaviors, alcohol use disorder, alcohol-related mortality and morbidity, and other alcohol-related problems and consequences. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 6, 2026**.

#### [NOT-DA-24-010](#) – **Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes**

The purpose of this Notice of special interest (NOSI) is to inform potential applicants to the National Institute on Drug Abuse ([NIDA](#)) of special interest in grant applications that examine the impact of changing state and local psychedelic and dissociative drug policies. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 8, 2026**.

#### [NOT-AA-23-011](#) – **Secondary Analyses of Existing Alcohol Research Data**

The purpose of this Notice is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This NOSI encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 6, 2026**.

#### [NOT-HL-23-090](#) – **Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment**

This NOSI aims to increase research to understand the heterogeneity of obesity phenotypes and the underlying mechanisms that protect against or increase risk for obesity and obesity-associated conditions. The objective is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 8, 2027**.

#### [NOT-CA-23-071](#) – **Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials**

The Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) announces this Notice to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials



Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. **Application Due Dates:** February 28, 2024 and June 30, 2025; **Expiration Date:** July 1, 2025.

## NIH Funding Opportunities

### NIH Funding Opportunities: Request for Applications (RFA)

#### NOVEMBER 2023 DUE DATES

[RFA-AG-24-028](#) – (R01 Clinical Trial Not Allowed)

[RFA-AG-24-029](#) – (R21 Clinical Trial Not Allowed)

#### **Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD**

The purpose of this Notice of Funding Opportunity (NOFO) is to invite innovative applications that explore how structural, community, and interpersonal mechanisms operate over the life course to shape health outcomes of middle- and older-age first-generation immigrant groups from racial and/or ethnic groups considered to be a minority in the US (see [OMB Directive 15](#)) and any resulting health disparities. The R01 initiative seeks to support the development of data, approaches, and measures to evaluate the impact of immigration and other associated factors on health (including cognitive health and AD/ADRD) in the US and understand any disparities among a variety of racial and ethnic subgroups. The R21 initiative solicits applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). **Application Due Date:** November 3, 2023; **Expiration Date:** November 4, 2023.

[RFA-AG-24-045](#) – (R01 Clinical Trial Required)

#### **Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults**

The National Institute on Aging (NIA) invites applications that propose human studies to better understand factors underlying response variability to exercise training in older adults. This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. Additionally, this NOFO encourages transdisciplinary studies utilizing innovative design methods and analytical approaches combined with clinical phenotyping to disentangle the complicated relationships between endogenous and exogenous factors that drive response variation to exercise. **Application Due Date:** November 3, 2023; **Expiration Date:** November 4, 2023.

[RFA-HD-24-011](#) – (U01 Clinical Trial Required)

#### **HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain: Acute Pain Clinical Trials Program**

This Notice is to advance the understanding, assessment, measurement, treatment, and prevention of pain in infants, children, and adolescents, including those with disabilities and/or experiencing health disparities. This NOFO is part of the NIH [Helping to End Addiction Long-Term \(HEAL\) Initiative](#), a trans-agency effort to fund research to find scientific solutions to the national opioid public health crisis (see below for additional HEAL details). **Application Due Date:** November 20, 2023; **Expiration Date:** November 21, 2023.

[RFA-HD-24-012](#) – (U24 Clinical Trial Not Allowed)

#### **HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discover Studies) Pain Program Resource and Data Center**

The NIH seeks applications for a single Resource and Data Center (RDC) to complement a broader HEAL program that is being developed to support the HEAL KIDS (Knowledge, Innovation, and Discovery Studies) Pain Program. Key responsibilities of the HEAL KIDS Pain RDC include: (1) Providing logistical support and coordination for this broader research program; (2) Providing data collection, curation, and harmonization support for this broader research program leveraging relevant data standards; and (3) facilitating submission of data to [HEAL-compliant data repositories](#) and registering [study level metadata with the HEAL Data](#)

[Platform](#), in alignment with the [HEAL Data Sharing Policy](#). **Application Due Date:** November 20, 2023; **Expiration Date:** November 21, 2023.

[RFA-MH-24-100](#) – (R21/R33 Clinical Trial Not Allowed)

**Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment**

The main objective of this NOFO is to accelerate the implementation of more targeted and sustainable interventions to improve HIV prevention, treatment, and care, which is closely aligned with the priorities of the NIMH Division of AIDS Research, the NIH Office of AIDS Research, and the U.S. Department of Health and Human Services. This NOFO aims to support phased collaborative data science and implementation science research projects that uses a multi-stage participatory simulation modeling approach to more effectively address the HIV prevention and treatment needs of the population. **Application Due Date:** November 22, 2023; **Expiration Date:** November 23, 2023.

[RFA-MH-24-160](#) – (R01 Clinical Trial Optional)

[RFA-MH-24-161](#) – (R21 Clinical Trial Optional)

[RFA-MH-24-162](#) – (r34 Clinical Trial Optional)

**Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention or Women**

This NOFO invites applications to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available. **Application Due Date:** November 22, 2023; **Expiration Date:** November 23, 2023.

**DECEMBER 2023 DUE DATES**

[RFA-OH-24-002](#) – (R21)

**Exploratory/Developmental Grants on Lifestyle Medicine Research Related to the World Trade Center Health Program**

Lifestyle medicine is a highly valuable, evidence-informed clinical approach focused on preventing, managing, and reversing many types of chronic diseases certified as WTC-related health conditions by the WTC Health Program. To help maximize the impact of the WTC Health Program FY2024 lifestyle medicine research, NIOSH seeks to achieve a suitable mix of projects and interventions focusing on the following sustainable health behaviors and lifestyle factors: nutrition and diet, sleep hygiene, stress management and positive psychology, physical activity, social connectedness, and avoidance of harmful substance use. All these sustainable health behaviors and lifestyle factors influence disease progression and recurrence, survival, quality of life, and other health-related outcomes among the 9/11-exposed population.

**Application Due Date:** December 5, 2023; **Expiration Date:** January 4, 2024.

[RFA-OH-24-003](#) – (R21 No Applications with Responders Accepted)

**Exploratory/Developmental Grants Related to the World Trade Center Survivors**

NIOSH is soliciting applications for scientifically rigorous research (42 U.S.C. §300mm–51) among screening-eligible and certified-eligible WTC survivors and similarly exposed populations in New York City in Manhattan between Houston Street and 14th Street and in Brooklyn to both address critical questions about physical and mental health conditions and provide practical treatment and diagnostic benefits for enrollees. Screening-eligible and certified-eligible WTC survivors (adults and children) include individuals who lived, worked, went to school, or attended child or adult day care in the [New York City \(NYC\) Disaster Area](#), as defined in [42 CFR 88.1](#), on September 11, 2001, or in the following days, weeks, or months and those otherwise meeting the eligibility criteria in 42 CFR [88.7](#) or [88.8](#). **Application Due** December 5, 2023; **Expiration:** January 4, 2024.

[RFA-OH-24-004](#) – (K01)

**World Trade Center Health Program Mentored Research Scientist Career Development Award**

The purpose of the NIOSH and WTC Health Program Mentored Research Scientist Career Development Award (K01) is to provide support and 75% “protected time” (up to 3 years) for an intensive, supervised (mentored) career development experience in WTC-related health research. This can facilitate the transition of junior research scientists from the mentored to the independent stages of their careers in WTC-related health research. **Application Due Date:** December 5, 2023; **Expiration Date:** January 4, 2024.

[RFA-OD-23-021](#) – (U01 Clinical Trial Required)

**Public Health Communication Messaging about the Continuum of Risk for Tobacco Products**

This Notice invites applications for a Cooperative Agreement that will utilize health communication research to better understand the impact that messaging about the continuum of risk for tobacco products may have on various segments of the population. Applications should consider effects on audiences for whom the messaging could potentially be useful (i.e., adults who use combustible products) and on those for whom the messaging could have negative consequences (e.g., youth). **Application Due Date:** December 6, 2023; **Expiration Date:** December 7, 2023.

[RFA-AA-23-005](#) – (R01 Clinical Trial Optional)

[RFA-AA-23-006](#) – (R34 Clinical Trial Optional)

**HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions**

This NOFO seeks to support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). The R01 supports secondary analysis of data from relevant clinical projects and archives, and to support new hypothesis-clarifying studies to identify how people with OUD-AUD are being treated and associated treatment outcomes, identify challenges for treating people with OUD-AUD, and formulating best treatment practices for this population. The R34 is to support clinical research project development, including piloting study design and research protocols, subject recruitment, and initiating data collection and analysis pertinent to studying treatment practices for people with OUD-AUD. **Application Due Date:** December 14, 2023; **Expiration Date:** December 15, 2023.

**2024 DUE DATES**

[RFA-NS-24-023](#) – (UG3/UH3 Clinical Trial Optional)

**HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials**

The purpose of this NOFO is to promote the discovery, development, and validation of real-world digital endpoints derived from data generated by existing remote or wearable devices. These endpoints will be used for monitoring the experience of pain, its progression, response to interventions, and impact on quality of life. **Application Due Date:** January 30, 2024; **Expiration Date:** January 31, 2024.

[RFA-DA-24-063](#) – (R01 Clinical Trial Not Allowed)

[RFA-DA-24-064](#) – (R21 Clinical Trial Not Allowed)

**HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose**

The purpose of this Notice is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. **Application Due Date:** February 1, 2024; **Expiration Date:** February 2, 2024.

[RFA-MH-25-125](#) – (R34 Clinical Trial Optional)

[RFA-MH-25-126](#) – (R01 Clinical Trial Optional)

**Systems-Level Risk Detection and Interventions to Reduce Suicide, ideation, and Behaviors in Youth from Underserved Populations**

The R34 initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among children, adolescents, and transition-age youth/young adults from underserved populations. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects.

The R01 proposal encourages services research aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI among adolescents and children from the targeted populations. **Application Due Dates:** February 20, 2024; **Expiration Date:** February 21, 2024.

[RFA-OD-23-013](#) – (R21 Clinical Trial Optional)

[RFA-OD-23-014](#) – (R01 Clinical Trial Optional)

**Understanding Chronic Conditions Understudied Among Women**

The purpose of this Funding Opportunity is to invite R21 applications on chronic conditions understudied



among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." **Application Due Date:** June 20, 2024; **Expiration Date:** June 21, 2024.

[RFA-DA-25-018](#) – (R34 Clinical Trial Optional)

**Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services**

This Notice will support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among survivors of sexual trafficking and sexual violence. **Application Due Date:** August 5, 2024; **Expiration Date:** August 6, 2024.

[RFA-DA-25-001](#) – (R01 Clinical Trial Optional)

[RFA-DA-25-002](#) – (R34 Clinical Trial Required)

**Addressing HIV in Highest Risk Sexual and Gender Minorities**

This initiative will support epidemiologic, intervention, or implementation research that increases public health capacity to reduce the number of new HIV infections among SGM persons. This Notice requires the inclusion of major stakeholders and potential end users of research findings as collaborators; this may include individuals involved in local or state HIV program planning and, particularly for intervention research, collaborations with service delivery organizations (e.g., CBOs/ASOs, health systems, Federally Qualified Health Centers) that can implement effective interventions in their settings. **Application Due Date:** August 14, 2024; **Expiration Date:** August 15, 2024.

[RFA-DA-25-003](#) – (UU01 Clinical Trial Not Allowed)

**Cohort Studies HIV/AIDS and Substance Use**

NIDA supports a program of longitudinal cohort studies that addresses the intersection of HIV and substance use. This program is a multidisciplinary platform to support basic, epidemiologic, and clinical research on HIV and HIV-associated co-morbidities and co-infections among populations with substance use and substance use disorders (SUDs) and to address research questions at the individual and population level. The purpose of this NOFO is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance use in alignment with [NIH-HIV research priorities](#) in order to inform policy or practice. **Application Due Date:** August 16, 2024; **Expiration Date:** August 17, 2024.

## MULTIPLE DUE DATES

[RFA-NS-24-021](#) – (R01 Clinical Trial Optional)

**HEAL Initiative: Understanding Individual Differences in Human Pain Conditions**

This Notice seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. **Application Due Date:** Multiple Dates; see announcement; **Expiration Date:** February 7, 2025.

[RFA-ES-23-011](#) - \_R21 Clinical Trial Not Allowed)

**Time-Sensitive Research Opportunities in Environmental Health Sciences**

This NOFO is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. **Application Due Dates:** Multiple Dates; see announcement; **Expiration Date:** December 2, 2025.

[RFA-OD-23-017](#) – (R01 Clinical Trial Optional)

**Tobacco Regulatory Science**

This Notice is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Projects must address the research

priorities related to the regulatory authority of the FDA Center for Tobacco Products (CTP). **Application Due Dates:** May 6, 2024, October 4, 2024, May 2, 2025.

[RFA-DA-24-037](#) – (R21 Clinical Trial Optional)

#### **Accelerating the Pace of Drug Abuse Research Using Existing Data**

The purpose of this Announcement is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors and related disorders, prevention of substance use and HIV, and health service utilization. **Application Due Dates:** November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.

[RFA-HG-23-017](#) – (R01 Clinical Trial Optional)

[RFA-HG-23-018](#) – (R21 Clinical Trial Optional)

#### **Investigator-Initiated Research in Genomics and Health Equity**

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. **Application Due Dates:** November 8, 2023, July 8, 2024, July 8, 2025.

[RFA-CA-23-042](#) – (F99/K00 Clinical Trial Not Allowed)

#### **The NCI Predoctoral to Postdoctoral Fellow Transition Award**

The objective of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to identify and encourage outstanding graduate students who are recognized by their institutions as having high potential and strong interest in pursuing careers as independent cancer researchers, and then to facilitate their successful transition to postdoctoral positions. **Application Due Dates:** November 17, 2023, November 19, 2024. **Expiration Date:** November 20, 2024.

[RFA-DA-25-019](#) (R01 Clinical Trial Required)

[RFA-DA-25-020](#) (R34 Clinical Trial Required)

#### **Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services**

The purpose of this Notice is to address research gaps in understanding how to improve health outcomes among persons who are at heightened risk for HIV or living with HIV, Hepatitis, and substance use in the US, and to inform novel strategies for integrating primary care, HIV, Hepatitis, and substance use disorder (SUD) prevention and treatment services. The NOFO will support research that promotes scalable strategies of integrated care and services designed to improve health outcomes related to HIV, Hepatitis B and C (optional) and SUD. **Application Due Dates:** August 20, 2024, March 19, 2025; **Expiration Date:** March 20, 2025.

### **NIH Funding Opportunities: Program Announcements Reviewed in an Institute (PAR)**

[PAR-23-174](#) – (R36 Clinical Trial Not Allowed)

#### **Aging Research Dissertation Awards to Promote Diversity**

This NOFO invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within [NIA's strategic priorities](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 17, 2024

[PAR-23-116](#) – (P30 Clinical Trial Not Allowed)

#### **Centers for AIDS Research**

The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-117](#) – (P30 Clinical Trial Not Allowed)

#### **Developmental Centers for AIDS Research**

The FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-269](#) – (DP1 Clinical Trial Optional)

**NIDA Avant-Garde Program for IV and Substance Use Disorder Research**

Applications responding to this FOA must propose projects that align with the high priority HIV/AIDS research areas as described in [NOT-OD-20-018](#). Areas of interest include innovative basic, clinical or translational research that may lead to improved preventive interventions or therapies; creative strategies to prevent HIV transmission; novel approaches to improve outcomes of HIV and HIV-related comorbidities; innovative ideas to improve health outcomes of people with SUD and are living with HIV; and cutting-edge approaches to eradicating HIV. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 15, 2025

[PAR-23-125](#) – (DP2 Clinical Trial Optional)

**Avenir Award Program for Research on Substance Use Disorders and HIV**

This Avenir program looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies at the nexus of substance use disorders (SUD) and HIV. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 16, 2025

[PAR-23-191](#) – (R21 Clinical Trial Optional)

**HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions**

This Notice, issued by the Fogarty International Center (FIC), seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing, testing and implementing appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 9, 2025

[PAR-23-190](#) – (R01 Clinical Trial Optional)

**Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries**

This NOFO issued by the Fogarty International Center (FIC) seeks to support research to develop and pilot test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The NOFO will also support interventions to address the multiple intersecting stigmas due to co-occurring diseases and/or conditions faced by PLWH. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 23, 2025

[PAR-23-236](#) – (R24 Clinical Trial Not Allowed)

**Early-stage Biomedical Data Repositories and Knowledgebases**

This Notice supports the development of early-stage or new data repositories or knowledgebases that could be valuable for the biomedical research community. The goal is to support pilot activities that demonstrate the need and potential impact of the data resource. The NOFO will also support transitioning resources that are currently supported as investigator-initiated research efforts into quality controlled, standards-based resources that address governance, and efficiency of operations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 26, 2026

[PAR-23-237](#) – (U24 Clinical Trial Not Allowed)

**Enhancement and Management of Established Biomedical Data Repositories and Knowledgebases**

This Notice of Funding Opportunity (NOFO) is designed to support established biomedical data repositories and knowledgebases as distinct and separate resources that have demonstrated impact and have potential for continued benefit to the community served. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 26, 2026

[PAR-23-122](#) – (R01 Clinical Trial Optional)

**Research With Activities Related to Diversity (ReWARD)**

The goal of the NIH ReWARD program is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-152](#) – (R21 Clinical Trial Optional)

[PAR-23-153](#) – (R01 Clinical Trial Optional)

#### **Impacts of Climate Change across the Cancer Control Continuum**

This Notice aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-155](#) – (R01 Clinical Trial Required)

#### **Understanding Expectancies in Cancer Symptom Management**

This NOFO is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAS-23-172](#) – (R34 Clinical Trials Optional)

[PAS-23-173](#) – (R01 Clinical Trials Optional)

#### **HIV Prevention and Alcohol**

The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-273](#) – (R01 Clinical Trial Required)

#### **Understanding Expectancies in Cancer Symptom Management**

This Notice will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-240](#) – (R25 Clinical Trial not Allowed)

#### **Alcohol and Other Substance Use Research Education Programs for Health Professionals**

The NIH Research Education Program supports research education activities in the mission areas of the NIH. This NOFO will support creative educational activities with a primary focus on Outreach. This is a broad category of activities that emphasizes the dissemination of biomedical, behavioral, and clinical research findings from research on alcohol and other substance use to health professionals engaged in direct patient care and clinical service delivery. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** May 26, 2026.

[PAR-23-253](#) – (UG3/UH3 Clinical Trial Optional)

#### **Device Based Treatments for Substance Use Disorders**

The purpose of this Notice is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 14, 2026.

[PAR-23-194](#) – (R36 Clinical Trials Not Allowed)

#### **Substance Use/Substance Use Disorder Dissertation Research Award**

The goal of this Notice is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Dissertation research topics should align with the National Institute on Drug Abuse (NIDA) strategic plan (<https://nida.nih.gov/about-nida/noras-blog/2022/09/nida-releases-its-2022-2026-strategic-plan>), or with the NIDA HIV/AIDS research priorities (<https://nida.nih.gov/about-nida/organization/offices/hiv-research-program-hrp/about-hiv-research-program>). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-23-254](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-255](#) – (R21 Clinical Trials Not Allowed)

## **Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes**

Through this NOFO, the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-23-249](#) – (R34 Clinical Trial Required)

[PAR-23-250](#) – (R01 Clinical Trial Required)

## **Alcohol Treatment, Pharmacotherapy, and Recovery Research**

This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-23-251](#) – (R01 Clinical Trial Optional)

[PAR-23-252](#) – (R34 Clinical Trial Optional)

## **Alcohol Health Services Research**

This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD). The five major areas of emphasis are: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-24-027](#) – (X01)

## **Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access**

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This Notice allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this can be found at: <https://nida.nih.gov/research/nida-research-programs-activities/population-assessment-tobacco-health-path-study/data-access>.

**Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 31, 2026

[PAR-23-170](#) – (R01 Clinical Trial Required)

## **Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities**

This Notice invites applications to test cancer preventive or screening interventions to reduce the burden of cancer in populations that experience health disparities. The Office of Disease Prevention (ODP) and participating NIH Institutes, Centers, and Offices (ICs) are issuing this to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

[PAR-23-244](#) – (R01 Clinical Trial Optional)

## **Population Approaches to Reducing Alcohol-related Cancer Risk**

This NOFO aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control.



**Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

[PAR-23-270](#) – (R01 Clinical Trial Required)

**Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations that Experience Health Disparities**

The purpose of this NOFO is to support research projects that test innovative approaches to implementing Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2027

[PAR-23-285](#) – (R34 Clinical Trial Optional)

[PAR-23-298](#) – (R01 Clinical Trial Optional)

[PAR-23-299](#) – (R21 Clinical Trials Optional)

**Intervention Research to Improve Native American Health**

The purpose of the R34 funding opportunity is to support planning and development, including pilot or feasibility research, to improve health in Native American populations. Proposed research may address health promotion, disease prevention, treatment, recovery, or services research to inform intervention implementation and dissemination. The R01 Notice is to support research on interventions to improve health in Native American populations. This includes 1) etiologic research that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests interventions for health promotion, prevention, treatment, or recovery, and 3) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. The R21 will support developmental/exploratory research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

[PAR-23-292](#) – (R01 Clinical Trial Optional)

**Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations**

Through this Notice, the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

## **NIH Funding Opportunities: Program Announcements (PA)**

The following opportunities have standard due dates unless noted otherwise:

[PA-23-260](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)**

Expiration Date: September 8, 2025

[PA-23-261](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)**

Expiration Date: September 8, 2025

[PA-23-262](#)

**Ruth I. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)**

Expiration Date: September 8, 2025

[PA-23-263](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)**

Expiration Date: September 8, 2025

**PA-23-271**

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)**

Expiration Date: September 8, 2025

**PA-23-272**

**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)**

Expiration Date: September 8, 2025

**Words to Live By**

“Experience is what you get while looking for something else” – Federico Fellini, film director

For more information on RAS services, visit our website at [sphhp.buffalo.edu/ras](http://sphhp.buffalo.edu/ras)

